GS-524 phase 1 trial
Ended Awarded Last action
- Contract number
- 75N91022F00004
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,686,999
Award facts
- Contract value 100% obligated
- $4,686,999.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$7,358,877 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $8,943,538 | |
| Funding Only Action | $678,696 | |
| Original award | $2,423,642 |
About this award
This is a $4,686,999.20 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is to support the President's Department of Government Efficiency Cost Efficiency Initiative through a Phase 1 trial, with a period of performance ending on July 6, 2026. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing comprehensive biomedical research and facilities support services. This contract does not have a set-aside designation, indicating Leidos' broad capabilities in supporting scientific research and government efficiency initiatives across various agencies and programs.
Quick answers
Who was awarded contract 75N91022F00004?
75N91022F00004 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on January 7, 2022.
How much is contract 75N91022F00004 worth?
The government has obligated $4,686,999 on 75N91022F00004.
Is contract 75N91022F00004 an order under another contract?
Yes. 75N91022F00004 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00004 competed?
The extent of competition for 75N91022F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award